A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess the safety and tolerability of ascending doses of TOL101 and the effectiveness of TOL101 to target and downregulate T cells in patients undergoing first renal transplantation
The following safety parameters will be monitored: Adverse events, standard laboratory safety evaluations (hematology and serum chemistries), symptom constellation indicating cytokine release syndrome, serum concentrations of cytokines and nitric oxide, malignancies, CMV viremia, BKV viremia, EBV viremia and other infections
6 months
Yes
Stuart Flechner, MD
Principal Investigator
The Cleveland Clinic
United States: Food and Drug Administration
TTI-121
NCT01154387
July 2010
June 2013
Name | Location |
---|---|
University of Michigan | Ann Arbor, Michigan 48109-0624 |
Cleveland Clinic Foundation | Cleveland, Ohio 44195 |
Medical University of South Carolina | Charleston, South Carolina 29425-0721 |
Montefiore Medical Center | Bronx, New York 10467-2490 |
Baylor University Medical Center | Dallas, Texas 75246 |
University of Utah | Salt Lake City, Utah |
University of Kentucky | Lexington, Kentucky 40536-0098 |
St Barnabas Medical Center | Livingston, New Jersey 07039 |
University of Colorado Denver | Denver, Colorado 80262 |
University of Virginia Health System | Charlottesville, Virginia 22903 |
Buffalo General Hospital | Buffalo, New York 14209 |
Baylor All Saints | Fort Worth, Texas 76104 |